CSTL (Castle Biosciences) Total Liabilities: $86.4 Mil (As of Mar. 2026)

What is Castle Biosciences Total Liabilities?

Castle Biosciences CSTL +6.07% 73 Total Liabilities is $86.4 Mil as of Mar. 2026. GuruFocus rates CSTL with a GF Score™ of 73/100 and a GF Value™ of $29.16 (Modestly Undervalued). The stock has 4 warning signs investors should review.

Castle Biosciences's Total Liabilities for the quarter that ended in Mar. 2026 was $86.4 Mil.

Castle Biosciences's quarterly Total Liabilities increased from Sep. 2025 ($95.74 Mil) to Dec. 2025 ($107.68 Mil) but then declined from Dec. 2025 ($107.68 Mil) to Mar. 2026 ($86.39 Mil).

Castle Biosciences's annual Total Liabilities increased from Dec. 2023 ($62.07 Mil) to Dec. 2024 ($75.40 Mil) and increased from Dec. 2024 ($75.40 Mil) to Dec. 2025 ($107.68 Mil).

Castle Biosciences Total Liabilities Related Terms

Castle Biosciences Total Liabilities Historical Data

* Premium members only.

The historical data trend for Castle Biosciences's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Castle Biosciences Total Liabilities Chart

Castle Biosciences Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

Total Liabilities

Get a 7-Day Free Trial

50.83

48.18

62.07

75.40

107.68

Castle Biosciences Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
Total Liabilities	Get a 7-Day Free Trial															61.41	89.35	95.74	107.68	86.39

73GF Score

Castle Biosciences Inc CSTL

Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Castle Biosciences Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Castle Biosciences's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	68.677	+	(35.171	+	1.5
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	2.335	+	0	+	0)
	=	107.7

Total Liabilities	=	Total Assets (A: Dec. 2025 )	-	Total Equity (A: Dec. 2025 )
	=	578.556	-	470.873
	=	107.7

Castle Biosciences's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	48.761	+	(33.803	+	1.5
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	2.325	+	0	+	0)
	=	86.4

Total Liabilities	=	Total Assets (Q: Mar. 2026 )	-	Total Equity (Q: Mar. 2026 )
	=	547.805	-	461.416
	=	86.4

Frequently Asked Questions Learn more about Total Liabilities →

What does a Total Liabilities of $86.4 Mil mean?

Castle Biosciences (CSTL) has a Total Liabilities of $86.4 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Castle Biosciences and its competitors.

Is Castle Biosciences' Total Liabilities too high?

Castle Biosciences' current Total Liabilities is $86.4 Mil. Overall, Castle Biosciences has a GF Score™ of 73/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.

How does Castle Biosciences' Total Liabilities compare to FLGT and MYGN?

Castle Biosciences' Total Liabilities of $86.4 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Total Liabilities for a Medical Diagnostics & Research company?

A good Total Liabilities depends on the Medical Diagnostics & Research industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Total Liabilities mean?

A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Castle Biosciences and its competitors. Castle Biosciences's current Total Liabilities is $86.4 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Castle Biosciences stock overvalued right now?

Based on GuruFocus' analysis, Castle Biosciences (CSTL) is currently considered Modestly Undervalued. The stock's GF Value™ is $29.16, compared to a current price of $24.21 — trading 17% below its estimated fair value. The current Total Liabilities is $86.4 Mil. Castle Biosciences' overall GF Score™ is 73/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Total Liabilities calculated?

Total Liabilities is calculated from a company's financial statements. For Castle Biosciences (CSTL), the current Total Liabilities is $86.4 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Castle Biosciences (CSTL) Overvalued in 2026?

Based on GuruFocus' analysis, Castle Biosciences stock appears to be undervalued. The current stock price of $24.21 is trading 17% below its estimated GF Value™ of $29.16. GuruFocus considers Castle Biosciences to be Modestly Undervalued.

Key valuation signals for CSTL:

Total Liabilities: $86.4 Mil
GF Value™: $29.16 vs. price of $24.21 (17% below fair value)
GF Score™: 73/100 with 4 warning signs

No single metric tells the full story. See the CSTL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Castle Biosciences Business Description

Industry Healthcare Medical Diagnostics & Research

Comparable Companies FLGT MYGN PRE IMDX OPK BDSX XGN FONR CDNA BNR TMO DHR SHSE:603259 XSWX:LONN IDXX A WAT NTRA IQV ILMN

Other Exchanges 086:Germany

Address 1500 West Parkwood Avenue, Suite 401, Friendswood, TX, USA, 77546

Website https://www.castlebiosciences.com

Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.

73GF Score

Get the complete analysis for CSTL

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$24.21

Price

$29.16

GF Value

View CSTL Analysis

See Total Liabilities data for all stocks →